key: cord-0993236-5ue1byjm
authors: Higuchi, Takatoshi; Nishida, Tsutomu; Iwahashi, Hiromi; Morimura, Osamu; Otani, Yasushi; Okauchi, Yukiyoshi; Yokoe, Masaru; Suzuki, Norihiro; Inada, Masami; Abe, Kinya
title: Early clinical factors predicting the development of critical disease in Japanese patients with COVID‐19: A single‐center, retrospective, observational study
date: 2020-11-01
journal: J Med Virol
DOI: 10.1002/jmv.26599
sha: b10377c883557089d3e642393b668e21d81e8ed3
doc_id: 993236
cord_uid: 5ue1byjm

The factors predicting the progression of coronavirus disease‐2019 (COVID‐19) from mild to moderate to critical are unclear. We retrospectively evaluated risk factors for disease progression in Japanese patients with COVID‐19. Seventy‐four patients with laboratory‐confirmed COVID‐19 were hospitalized in our hospital between February 20, 2020, and June 10, 2020. We excluded asymptomatic, non‐Japanese, and pediatric patients. We divided patients into the stable group and the progression group (PG; requiring mechanical ventilation). We compared the clinical factors. We established the cutoff values (COVs) for significantly different factors via receiver operating characteristic curve analysis and identified risk factors by univariate regression. We enrolled 57 patients with COVID‐19 (median age 52 years, 56.1% male). The median time from symptom onset to admission was 8 days. Seven patients developed critical disease (PG: 12.2%), two (3.5%) of whom died; 50 had stable disease. Univariate logistic analysis identified an elevated lactate dehydrogenase (LDH) level (COV: 309 U/l), a decreased estimated glomerular filtration rate (eGFR; COV: 68 ml/min), lymphocytopenia (COV: 980/μl), and statin use as significantly associated with disease progression. However, in the Cox proportional hazards analysis, lymphocytopenia at admission was not significant. We identified three candidate risk factors for progression to critical COVID‐19 in adult Japanese patients: statin use, elevated LDH level, and decreased eGFR.

. It has rapidly spread and resulted in a pandemic. The clinical presentation of patients with COVID-19 ranges from asymptomatic to mild to critical, and the disease can lead to death. The WHO classified COVID-19 into four severity levels: mild, moderate, severe, and critical. 1 The proportion of patients with severe or critical disease may vary with location, but most patients have mild to moderate disease. 2, 3 However, some patients rapidly progress to critical illness. 4 The mortality risk dramatically increases once a patient develops critical disease. 5 Therefore, the early prediction of progression to critical COVID-19 is required to enable the timely initiation of interventions to improve the prognosis. In addition, ethnic differences may affect the risk factors because of the different extent of the pandemic in various regions. However, there is no established evidence of predictive factors for the development of critical COVID-19 in the Japanese population. Our hospital is a medium-volume hospital with 613 beds, including 14 in the Infectious Disease Unit, in an urban area of Osaka Prefecture, Japan. It is also one of 351 designated medical institutions for Type II infectious diseases in Japan, with a total of 1758 beds. We have accepted patients with COVID-19 since February 2020 and have expanded the number of beds for infectious disease patients from 14 to 45 to make more room for COVID-19 patients. In the present study, we retrospectively examined the risk factors for progression to critical disease in Japanese patients with COVID-19 using clinical characteristics and laboratory findings in a single hospital.

This study was a retrospective single-center cohort study that examined a total of 75 consecutive patients with laboratory-confirmed COVID-19 from February 20, 2020 to June 10, 2020. We followed the patients until July 7, 2020. In the present study, various reverse transcription-polymerase chain reaction (RT-PCR) assays were used, but all findings were based on the results of tests by public health centers in the Osaka area in Japan. 

We provided basic supportive care, including supplemental oxygen, and treatment with acetaminophen, antibiotics, and mechanical ventilatory support when indicated.

Regarding specific medications, we used ciclesonide for patients with lung infiltrates on imaging, hydroxychloroquine for patients with a high fever (higher than 38℃) or diarrhea, and favipiravir for patients with moderate pneumonia, according to the advice of respiratory disease specialists.

A diagnosis of laboratory-confirmed COVID-19 was made in cases of the positive direct detection of SARS-CoV-2 nucleic acid by RT-PCR. 6 The classification of the severity of COVID-19 was as follows: (1) mild to moderate disease with or without pneumonia; (2) severe disease with dyspnea, a respiratory rate more than or equal to 30 breaths/min, a blood oxygen saturation level less than or equal to 93%, a PaO 2 /FiO 2 ratio less than 300, and/or lung infiltrates in more than 50% of the lung field within 24-48 h; and (3) critical disease with respiratory failure, septic shock, or multiple organ dysfunction/ failure according to the criteria in the Report of the WHO-China Joint Mission on COVID-19. 1 In the present study, progression was defined when a patient required mechanical ventilatory support.

The medians and interquartile ranges (IQRs) are reported for continuous variables. Categorical variables are summarized as frequencies (percentages). We used the values of the potential risk factors affecting disease progression measured at admission, and there was consequently some missing data. Missing continuous variables were imputed using a matrix imputation method, and missing categorical variables were imputed using random proportional methods. Differences in variables between the SG and PG were evaluated using Fisher's exact test for categorical data and the Mann-Whitney U test for continuous data. For the factors that differed significantly between the two groups and could be used to differentiate between the SG and PG, we performed receiver operating characteristic (ROC) curve analysis to determine the cutoff values (COVs) for predicting disease progression. Then, we used a univariate logistic regression model to obtain the odds ratios (ORs) with 95% confidence intervals (CIs) between the two groups according to the COVs for the significant factors. We defined the observation time as the interval from the onset of symptoms to the development of critical disease or discharge. The cumulative rates of progression to critical disease were calculated using the Kaplan-Meier method and compared using the log-rank test. Similarly, we used univariate Cox proportional hazards models to obtain the hazard ratios (HRs) with 95% CIs.

All reported p values were two-sided, and p < .05 was considered significant. Statistical analyses were performed with JMP statistical software (ver. 14.3, SAS Institute, Inc.).

All consecutive patients with COVID-19 hospitalized at Toyonaka Municipal Hospital between February 20 and June 10, 2020, were enrolled. There were a total of 74 patients with laboratory-confirmed COVID-19. Among these patients, we excluded seven asymptomatic patients, five readmitted patients, one patient transferred from another hospital, seven non-Japanese patients, and three patients younger than 16 years of age (some patients were included in more than one of these categories). Figure 1 shows the flow chart of patient enrollment. By the end of the follow-up period, all patients had been discharged, and we ultimately enrolled a total of 57 patients with newly diagnosed laboratory-confirmed mild to moderate or severe COVID-19. 

Patients with mild to moderate or severe COVID-19 N = 57

Compared with the SG, the PG had a significantly higher proportion of patients using statins, a lower lymphocyte count, a higher lactate dehydrogenase (LDH) level, a higher C-reactive protein (CRP) level, a higher blood urea nitrogen (BUN) level, and a lower estimated glomerular filtration rate (eGFR; were significantly associated with disease progression (Table 4) .

A plot of the progression-free intervals of the 57 patients is shown in Figure 2A . Univariate Cox regression analysis showed that statin use (HR: 6.28, p = .0167), an elevated LDH level (HR: 11.0, p = .0265), and a decreased eGFR (OR: 10.2 p = .0315) but not lymphocytopenia were significantly associated with disease progression ( Figure 2 ). Regarding clinical factors, advanced age and male sex were reported to be significant risk factors for disease progression, 10-12 but we did not identify these clinical factors as risk factors. Advanced age and comorbid conditions such as diabetes have been reported as risk factors for mortality, 1,7,13 although severe disease can occur in healthy individuals of any age. 13, 14 In the present study, we did not identify clinical background parameters as risk factors; however, both of our patients who died were men with diabetes aged 70 years or older, which supports the above previous reports.

In the present study, statin use was identified as a significant risk factor for the development of critical disease. Statins have antiinflammatory, antithrombotic, and immunomodulatory effects. 15, 16 Two observational studies of hospitalized patients with influenza during the 2009 H1N1 pandemic revealed reductions of 41% 17 and 59% 18 in 30-day mortality rates associated with the use of statins.

Those studies showed that statin use could decrease the disease severity in hospitalized patients with influenza. However, a later F I G U R E 2 Overall progression-free interval in patients with mild to moderate COVID-19. Significant differences were found in the progression-free interval between patients stratified by statin use, LDH levels and eGFRs at admission. COVID-19, coronavirus disease-2019; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase related to ethnic differences. In the symptomatic Japanese cohort in this study, 65% had mild to moderate disease, and 35% had severe disease; the condition of 12.2% of the patients deteriorated, and two died (3.5%). In a large cohort of Chinese patients, including approximately 44,500 patients with confirmed COVID-19, 81% of the cases were classified as mild, 14% as severe, and 5% as critical, and the mortality rate was 2.3%. 13 The outcomes in our Japanese cohort were similar to or worse than those in that Chinese population, and there seemed to be no ethnic differences between that Chinese population and the Japanese patients in our cohort.

This study has several limitations due to its retrospective nature.

First, we enrolled only a small number of COVID-19 patients. Consequently, we did not perform multivariate analysis. Second, our data set had missing data because we were not accustomed to treating COVID-19 patients and avoided unnecessary or nonurgent contact with these patients to reduce the risk of infection. Therefore, we statistically handled missing data using imputation methods in statistical software.

In conclusion, we report for the first time three candidate risk factors for disease progression in Japanese adult patients with mild to moderate COVID-19: statin use, an elevated LDH level, and a decreased eGFR.

We thank all medical staff members and doctors at Toyonaka Municipal Hospital. The collaborators involved in the study are as follows: Sanae Fukuda, Kazumi Ohkubo (Nursing Department), Dr.

REFERENCES 1. Report of the WHO-China Joint Mission on Coronavirus Disease

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Early prediction of disease progression in 2019 novel coronavirus pneumonia patients outside Wuhan with CT and clinical characteristics

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

Initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak -United States

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Clinical characteristics of coronavirus disease 2019 in China

Clinical features and progression of acute respiratory distress syndrome in coronavirus disease

Risk factors for disease progression in patients with mild to moderate COVID-19-a multi-center observational study

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

Antiinflammatory and immunomodulatory effects of statins

Statins as antithrombotic drugs

Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study

Early clinical factors predicting the development of critical disease in Japanese patients with COVID-19: A single-center, retrospective, observational study

The authors report that they have no conflicts of interest. The authors alone are responsible for the content and writing of this paper. 

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

http://orcid.org/0000-0003-4037-9003